<DOC>
	<DOCNO>NCT01061996</DOCNO>
	<brief_summary>Primary Objective Safety : assess safety basiliximab 40 mg , give every 4 week , subject ulcerative colitis complete previous basiliximab study . Secondary Objectives : evaluate efficacy assess immunogenicity multiple-dose maintenance regimen population</brief_summary>
	<brief_title>Basiliximab Maintenance Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Previously meet eligibility criterion previous basiliximab UC study 2 . Must total Mayo score entry consistent clinical response clinical remission . 3 . Signed current IRB/IECapproved inform consent form 4 . Females childbearing potential must use effective birth control method , willing continue birth control study , 4 month last dose study drug . 5 . Females nonchildbearing potential surgically sterile ( bilateral tubal ligation surgery least 6 month study entry , hysterectomy , bilateral oophorectomy least 2 month study entry ) postmenopausal least 2 year . 1 . Subject severely ill , evidence 6 episode loose stool , bloody , 24hour period within prior 7 day , concurrent follow systemic feature : Heart rate &gt; 90 beats/min rest Temperature &gt; 37.8 degree C Hemoglobin &lt; 10.5 g/dL 2 . Subject currently receive restricted/prohibited concomitant medication 3 . Subject undergone colectomy ( total , subtotal ) 4 . Subject pregnant breastfeeding 5 . Prior noncompliance previous study visit schedule requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Ulcerative Colitis</keyword>
</DOC>